Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
Centre hospitalier de l'Université de Montréal (CHUM)
National Cancer Institute (NCI)
Centre Oscar Lambret
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
Centre Oscar Lambret
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Grupo Español de Investigación en Cáncer de Ovario
Artios Pharma Ltd
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Genelux Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Carilion Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
Zhejiang University
Timser SAPI de CV
Beijing Biotech
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
GI Innovation, Inc.